Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Personalized oncology: genomic screening in phase 1

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Primary antibiotic resistance of Helicobacter pylori strains among adults and children in a tertiary referral centre in Lithuania

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A short history of microbial biofilms and biofilm infections

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Biofilms and host response - helpful or harmful

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Diagnosis of biofilm infections in cystic fibrosis patients

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Acinar cystic transformation of the pancreas: Report of a case and a review of the literature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Improvements in cancer genomics and tumor biology have reinforced the evidence of cancer development driven by numerous genomic alterations. Advanced genomics technology can be used to characterize genomic alterations that potentially drive tumor growth. With the possibility of screening thousands of genes simultaneously, personalized molecular medicine has become an option. New treatments are being investigated in phase 1 trials around the world. Traditionally, the goal of phase 1 studies was to determine the optimal dose and assess dose-limiting toxicity of a potential new experimental drug. Only a limited number of patients will benefit from the treatment. However, introducing genomic mapping to select patients for early clinical trials with targeted molecular therapy according to the genomic findings, may lead to a better outcome for the patient, an enrichment of phase 1 trials, and thereby accelerated drug development. The overall advantage is to determine which mutation profiles correlate with sensitivity or lack of resistance to specific targeted therapies. The utility and current limitations of genomic screening to guide selection to Phase 1 clinical trial will be discussed.

OriginalsprogEngelsk
TidsskriftAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica
Vol/bind122
Udgave nummer8
Sider (fra-til)723-33
Antal sider11
ISSN0903-4641
DOI
StatusUdgivet - aug. 2014

ID: 44662957